The Surrey and Borders Partnership NHS foundation trust is recruiting participants aged 55 to 80 for an international trial of the drug Trontinemab. By targeting amyloid plaques in people who show early biomarkers but no memory loss, the study aims to determine if dementia can be prevented before symptoms ever emerge.